In the nucleus of human cells sit our chromosomes, comprised mainly of tightly wound DNA. In some cells, however, some pieces of genetic material that exist within the nucleus are not attached to a chromosome—and a new company, Boundless Bio, believes these “extra” pieces of DNA play a key role in driving some especially aggressive solid-tumor cancers.

The San Diego-based biotech came out of stealth mode Thursday with an announcement that it had raised a $46.4 million Series A financing round to fund the development of cancer drugs targeting tumors that have what’s known as extrachromosomal DNA.

Zach Hornby, former chief… Read more »

UNDERWRITERS AND PARTNERS